Efficacy , Tolerability , and Dose-Dependent Effects of Opioid Analgesics for LowBack Pain

RESULTS Of 20 included RCTs of opioid analgesics (with a total of 7925 participants), 13 trials (3419 participants) evaluated short-term effects on chronic low back pain, and no placebo-controlled trials enrolled patients with acute low back pain. In half of these 13 trials, at least 50% of participants withdrew owing to adverse events or lack of efficacy. There was moderate-quality evidence that opioid analgesics reduce pain in the short term; mean difference (MD), −10.1 (95% CI, −12.8 to −7.4). Meta-regression revealed a 12.0 point greater pain relief for every 1 log unit increase in morphine equivalent dose (P = .046). Clinically important pain relief was not observed within the dose range evaluated (40.0-240.0-mg morphine equivalents per day). There was no significant effect of enrichment study design.

[1]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[2]  J P Vandenbroucke,et al.  Bias in meta-analysis detected by a simple, graphical test , 1998 .

[3]  M. Roland,et al.  The Roland-Morris Disability Questionnaire and the Oswestry Disability Questionnaire. , 2000, Spine.

[4]  T. Schnitzer,et al.  Efficacy of tramadol in treatment of chronic low back pain. , 2000, The Journal of rheumatology.

[5]  R. Raffa.  Pharmacology of oral combination analgesics: rational therapy for pain , 2001, Journal of clinical pharmacy and therapeutics.

[6]  H. Daniell.  Hypogonadism in men consuming sustained-action oral opioids. , 2002, The journal of pain : official journal of the American Pain Society.

[7]  S. Ludwig,et al.  Low-Serum Cortisol Associated With Opioid Use: Case Report and Review of the Literature , 2002 .

[8]  L. Bouter,et al.  Muscle Relaxants for Nonspecific Low Back Pain: A Systematic Review Within the Framework of the Cochrane Collaboration , 2003, Spine.

[9]  Catherine Sherrington,et al.  Reliability of the PEDro scale for rating quality of randomized controlled trials. , 2003, Physical therapy.

[10]  R. Karim,et al.  Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient study. , 2003, Clinical therapeutics.

[11]  G. Waddell,et al.  Rehabilitation Following First-Time Lumbar Disc Surgery: A Systematic Review Within the Framework of the Cochrane Collaboration , 2003, Spine.

[12]  P. Peloso,et al.  Analgesic efficacy and safety of tramadol/ acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial. , 2004, The Journal of rheumatology.

[13]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.

[14]  J. Gimbel,et al.  Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. , 2005, The journal of pain : official journal of the American Pain Society.

[15]  Karen Simpson,et al.  Transdermal Fentanyl Versus Sustained Release Oral Morphine in Strong-Opioid Naïve Patients With Chronic Low Back Pain , 2005, Spine.

[16]  A. Muñoz,et al.  Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. , 2005, The journal of pain : official journal of the American Pain Society.

[17]  A. Muñoz,et al.  Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994–2004 , 2005, Pharmacoepidemiology and drug safety.

[18]  S. Perrot,et al.  Efficacy and tolerability of paracetamol/tramadol (325 mg/37.5 mg) combination treatment compared with tramadol (50 mg) monotherapy in patients with subacute low back pain: a multicenter, randomized, double-blind, parallel-group, 10-day treatment study. , 2006, Clinical therapeutics.

[19]  Nora D Volkow,et al.  Major increases in opioid analgesic abuse in the United States: concerns and strategies. , 2006, Drug and alcohol dependence.

[20]  L. Burns,et al.  Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. , 2006, The journal of pain : official journal of the American Pain Society.

[21]  Nathaniel Katz,et al.  A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain* , 2007, Current medical research and opinion.

[22]  Bridget A. Martell,et al.  Systematic Review: Opioid Treatment for Chronic Back Pain: Prevalence, Efficacy, and Association with Addiction , 2007, Annals of Internal Medicine.

[23]  R. Deyo,et al.  Nonsteroidal Anti-Inflammatory Drugs for Low Back Pain: An Updated Cochrane Review , 2008, Spine.

[24]  T. Gana,et al.  Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. , 2018, Journal of opioid management.

[25]  S. Datta,et al.  Opioid complications and side effects. , 2008, Pain physician.

[26]  S. Tripathi,et al.  Epidemiology of regular prescribed opioid use: results from a national, population-based survey. , 2008, Journal of pain and symptom management.

[27]  Peter Croft,et al.  Interpreting Change Scores for Pain and Functional Status in Low Back Pain: Towards International Consensus Regarding Minimal Important Change , 2008, Spine.

[28]  David Cella,et al.  Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. , 2008, The journal of pain : official journal of the American Pain Society.

[29]  N. D. de Morton.  The PEDro scale is a valid measure of the methodological quality of clinical trials: a demographic study. , 2009, The Australian journal of physiotherapy.

[30]  C. Rutter,et al.  Trends in long‐term opioid therapy for chronic non‐cancer pain , 2009, Pharmacoepidemiology and drug safety.

[31]  Lisa Hartling,et al.  Risk of bias versus quality assessment of randomised controlled trials: cross sectional study , 2009, BMJ : British Medical Journal.

[32]  L. Macedo,et al.  There was evidence of convergent and construct validity of Physiotherapy Evidence Database quality scale for physiotherapy trials. , 2010, Journal of clinical epidemiology.

[33]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[34]  C. Rauschkolb,et al.  Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study , 2010, Expert opinion on pharmacotherapy.

[35]  M. Hale,et al.  Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain , 2010, Current medical research and opinion.

[36]  S. Rashiq,et al.  Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. , 2010, Pain research & management.

[37]  Helena Britt,et al.  Low back pain and best practice care: A survey of general practice physicians. , 2010, Archives of internal medicine.

[38]  T. Tzschentke,et al.  [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview]. , 2011, Schmerz.

[39]  Amanda F. Petrik,et al.  Opioids for Back Pain Patients: Primary Care Prescribing Patterns and Use of Services , 2011, The Journal of the American Board of Family Medicine.

[40]  E. Irvin,et al.  A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain. , 2011, Pain research & management.

[41]  Raimondo Bruno,et al.  Prescription of opioid analgesics and related harms in Australia , 2011, The Medical journal of Australia.

[42]  S. Ripa,et al.  Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. , 2011, Journal of pain and symptom management.

[43]  S. Ripa,et al.  Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. , 2011, The journal of pain : official journal of the American Pain Society.

[44]  Augusto Caraceni,et al.  Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. , 2011, Journal of pain and symptom management.

[45]  L. Manchikanti,et al.  A comprehensive review of opioid-induced hyperalgesia. , 2011, Pain physician.

[46]  M. Angst,et al.  Analgesic tolerance without demonstrable opioid-induced hyperalgesia: A double-blinded, randomized, placebo-controlled trial of sustained-release morphine for treatment of chronic nonradicular low-back pain , 2012, PAIN®.

[47]  Chris G Maher,et al.  Drugs for relief of pain in patients with sciatica: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[48]  G. Cummings,et al.  Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. , 2012, Journal of evaluation in clinical practice.

[49]  C. Guetti,et al.  Tramadol Extended-Release for the Management of Pain due to Osteoarthritis , 2013, ISRN Pain.

[50]  Chong-Suh Lee,et al.  A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of the extended-release tramadol hydrochloride/acetaminophen fixed-dose combination tablet for the treatment of chronic low back pain. , 2013, Clinical therapeutics.

[51]  C. Terwee,et al.  Spinal Manipulative Therapy for Acute Low Back Pain: An Update of the Cochrane Review , 2013, Spine.

[52]  Alan D. Lopez,et al.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[53]  I. Sutton,et al.  Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study. , 2013, Pain research & management.

[54]  Bernadette A. Thomas,et al.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[55]  S. Atlas,et al.  Opioids compared to placebo or other treatments for chronic low-back pain. , 2013, The Cochrane database of systematic reviews.

[56]  R. Chou,et al.  Opioid Prescribing: A Systematic Review and Critical Appraisal of Guidelines for Chronic Pain , 2014, Annals of Internal Medicine.

[57]  S. Atlas,et al.  Opioids Compared With Placebo or Other Treatments for Chronic Low Back Pain: An Update of the Cochrane Review , 2014, Spine.

[58]  R. Rauck,et al.  Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study. , 2014, Pain medicine.

[59]  P. Dijkstra,et al.  Do analgesics improve functioning in patients with chronic low back pain? An explorative triple-blinded RCT , 2014, European Spine Journal.

[60]  R. Deyo,et al.  Opioids for low back pain , 2015, BMJ : British Medical Journal.

[61]  R. Chou,et al.  2015 Updated Method Guideline for Systematic Reviews in the Cochrane Back and Neck Group , 2015, Spine.

[62]  R. Dart,et al.  Trends in opioid analgesic abuse and mortality in the United States. , 2015, The New England journal of medicine.

[63]  R. Chou,et al.  The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop , 2015, Annals of Internal Medicine.